Polyphenol-mediated microbiome modulation in STEMI patients: a pilot study

Issilbayeva A. Sergazy S. Zhashkeyev A. Gulyayev A. Kozhakhmetov S. Shulgau Z. Nurgaziyev M. Nurgaziyeva A. Zhetkenev S. Mukhanbetzhanov N. Jarmukhanov Z. Mukhanbetzhanova Z. Vinogradova E. Zhumadilov Z. Kushugulova A. Aljofan M.
2025 Frontiers Media SA

Frontiers in Medicine
2025 #12

Introduction: This study investigates the effects of polyphenol supplementation on gut microbiome composition and cardiovascular health in patients with ST-segment elevation myocardial infarction (STEMI). Methods: Double-blind randomized control trial where participants received either polyphenol supplementation or placebo for 3 months, after which composition of the gut microbiome; clinical and laboratory parameters, including TMAO levels and oxidative stress levels, were assessed. Results: The stable TMAO levels (from 0.5 [0.2–0.9] to 0.4 [0.3–0.9] μmol, p > 0.05) were observed in the polyphenol group, compared to the increase observed in the placebo group (from 0.5 [0.3–0.6] to 0.7 [0.5–1.4] μmol, p < 0.001). Polyphenol supplementation significantly decreased the Firmicutes/Bacteroidetes ratio (p = 0.04) and increased beneficial bacteria such as Roseburia (p = 0.01), Agathobaculum sp. (p = 0.004), Alistipes finegoldii (p = 0.04) and Sellimonas (p = 0.002). Predicted metabolic pathways analysis supports potential mechanisms linking polyphenol intake to microbiome modulation and TMAO regulation. Conclusion: Our findings demonstrate that polyphenol supplementation maintains stable TMAO levels by restructuring gut microbiome composition in STEMI patients, evidenced by a more focused microbiome with a significant increase in beneficial butyrate-producing bacteria (Roseburia, Agathobaculum sp., Alistipes finegoldii, and Sellimonas) and a decreased Firmicutes/Bacteroidetes ratio, suggesting microbiome-mediated cardioprotective effects. While promising,l our preliminary findings require further studies with larger cohorts and more advanced sequencing methods to establish their significance for cardiovascular health. Clinical trial registration: ClinicalTrial.gov, identfier: NCT06573892. Copyright

16S rRNA sequencing , gut microbiome , polyphenol , STEMI , TMAO

Text of the article Перейти на текст статьи

National Laboratory Astana, Center for Life Sciences, Nazarbayev University, Astana, Kazakhstan
Karaganda Medical University, Karaganda, Kazakhstan
Department of Surgery, Nazarbayev University School of Medicine, Astana, Kazakhstan
Department of Biomedical Sciences, Nazarbayev University School of Medicine, Astana, Kazakhstan

National Laboratory Astana
Karaganda Medical University
Department of Surgery
Department of Biomedical Sciences

10 лет помогаем публиковать статьи Международный издатель

Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026